Objective
The pneumococcus (Streptococcus pneumoniae) is the predominant cause of community-acquired pneumonia and causes otitis media, sinusitis, meningitis and sepsis. The increased serotype replacement and antibiotic resistance, reinforces the necessity of developing alternative treatment strategies for this pathogen. Monoclonal antibodies that boost the host immune system are attractive candidates to fight the high rates of morbidity and mortality due to this important human pathogen. Antibodies recognizing bacterial surface structures could be used to trigger activation of the complement cascade and subsequent bacterial killing. However, no significant progress has been made in the direction of immune system boosting therapies against pneumococci, mainly caused by our limited insights into antibody-driven immune activation on bacteria. With this proposal, I aim to study whether complement-enhancing monoclonal antibodies can be used as treatment against pneumococci. Through a combination of advanced sequencing approaches and functional complement activation assays, I will first identify antibodies against S. pneumoniae driving potent complement activation. Then I will use my expertise in S. pneumoniae infection models to unravel whether monoclonal antibodies eliciting complement are effective in pneumococcal killing in vitro and in vivo. The work proposed represents a first systematic approach to design effective therapeutic antibodies against S. pneumoniae that function via enhanced complement activation. Altogether, a better understanding of antibody-dependent complement activation on bacteria will create new avenues for the design of new therapeutic strategies to improve both antibody therapies and vaccination strategies in diseases caused by pathogenic bacteria.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences clinical medicine pneumology
- social sciences sociology demography mortality
- natural sciences biological sciences microbiology bacteriology
- medical and health sciences basic medicine immunology immunotherapy
- medical and health sciences basic medicine pharmacology and pharmacy drug resistance antibiotic resistance
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
MSCA-IF-EF-ST - Standard EF
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-MSCA-IF-2017
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
3584 CX Utrecht
Netherlands
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.